Zacks: Brokerages Expect Omnicell, Inc. (OMCL) Will Announce Quarterly Sales of $204.19 Million

Wall Street analysts forecast that Omnicell, Inc. (NASDAQ:OMCL) will post sales of $204.19 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Omnicell’s earnings. The highest sales estimate is $205.05 million and the lowest is $203.49 million. Omnicell reported sales of $171.97 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 18.7%. The company is expected to announce its next quarterly earnings results on Wednesday, February 21st.

On average, analysts expect that Omnicell will report full-year sales of $204.19 million for the current year, with estimates ranging from $721.71 million to $723.40 million. For the next fiscal year, analysts anticipate that the firm will report sales of $800.24 million per share, with estimates ranging from $796.19 million to $805.52 million. Zacks’ sales calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Omnicell.

Omnicell (NASDAQ:OMCL) last announced its earnings results on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.42. Omnicell had a negative net margin of 0.51% and a negative return on equity of 0.79%. The business had revenue of $186.78 million during the quarter, compared to analyst estimates of $192.45 million. During the same period in the previous year, the business posted $0.40 earnings per share. Omnicell’s revenue for the quarter was up 5.7% on a year-over-year basis.

OMCL has been the subject of several research analyst reports. Benchmark lifted their target price on shares of Omnicell from $55.00 to $67.00 and gave the company a “buy” rating in a research report on Tuesday, September 5th. Oppenheimer reiterated a “buy” rating and set a $55.00 target price on shares of Omnicell in a research report on Thursday, October 19th. Cantor Fitzgerald lifted their target price on shares of Omnicell to $58.00 and gave the company an “overweight” rating in a research report on Friday, October 27th. Craig Hallum reiterated a “buy” rating and set a $62.00 target price (up from $52.00) on shares of Omnicell in a research report on Monday, October 30th. Finally, Zacks Investment Research lowered shares of Omnicell from a “hold” rating to a “strong sell” rating in a research report on Wednesday, November 1st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $55.14.

In other news, CFO Peter J. Kuipers sold 1,926 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $51.69, for a total value of $99,554.94. Following the completion of the sale, the chief financial officer now directly owns 40,544 shares in the company, valued at approximately $2,095,719.36. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Dan S. Johnston sold 14,613 shares of the business’s stock in a transaction that occurred on Friday, November 17th. The stock was sold at an average price of $47.81, for a total transaction of $698,647.53. Following the completion of the sale, the executive vice president now owns 43,621 shares of the company’s stock, valued at $2,085,520.01. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 31,090 shares of company stock valued at $1,510,221. Company insiders own 3.77% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Pinebridge Investments L.P. raised its holdings in Omnicell by 1.6% during the 2nd quarter. Pinebridge Investments L.P. now owns 4,896 shares of the company’s stock valued at $211,000 after buying an additional 76 shares during the last quarter. Arizona State Retirement System raised its holdings in Omnicell by 0.5% during the 2nd quarter. Arizona State Retirement System now owns 19,384 shares of the company’s stock valued at $835,000 after buying an additional 100 shares during the last quarter. 1st Global Advisors Inc. raised its holdings in Omnicell by 1.5% during the 2nd quarter. 1st Global Advisors Inc. now owns 7,948 shares of the company’s stock valued at $343,000 after buying an additional 120 shares during the last quarter. Sawgrass Asset Management LLC raised its holdings in Omnicell by 4.6% during the 2nd quarter. Sawgrass Asset Management LLC now owns 7,525 shares of the company’s stock valued at $324,000 after buying an additional 330 shares during the last quarter. Finally, Municipal Employees Retirement System of Michigan raised its holdings in Omnicell by 5.3% during the 2nd quarter. Municipal Employees Retirement System of Michigan now owns 8,780 shares of the company’s stock valued at $378,000 after buying an additional 440 shares during the last quarter. Hedge funds and other institutional investors own 99.61% of the company’s stock.

Shares of Omnicell (NASDAQ:OMCL) traded down $0.10 during trading on Friday, reaching $49.85. 26,322 shares of the company’s stock traded hands, compared to its average volume of 254,604. Omnicell has a twelve month low of $31.85 and a twelve month high of $55.40. The company has a debt-to-equity ratio of 0.38, a current ratio of 1.53 and a quick ratio of 1.08.

COPYRIGHT VIOLATION WARNING: This piece was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/14/zacks-brokerages-expect-omnicell-inc-omcl-will-announce-quarterly-sales-of-204-19-million.html.

Omnicell Company Profile

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Get a free copy of the Zacks research report on Omnicell (OMCL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply